Peptide receptor–mediated radiotherapy of neuroendocrine and other somatostatin receptor–
positive tumors with radiolabeled somatostatin analogs has been applied in several …

111In-Diethylenetriaminepentaacetic acid-octreotide generally is used for the scintigraphic
imaging of neuroendocrine and other somatostatin receptor–positive tumors. On the basis of …

As scintigraphy with [111 In-DTPA 0] octreotide has become a standard technique in
analysing somatostatin receptor-receptor positive lesions such as neuroendocrine tumours …

This review focuses on the present status of kidney protection during peptide receptor
radionuclide therapy (PRRT) using radiolabelled somatostatin analogues. This treatment …

Purpose Peptide receptor radionuclide therapy using β-emitting radiolabelled somatostatin
analogues like DOTA, Tyr 3-octreotate shows beneficial results in patients suffering from …

Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs such
as octreotide is an effective therapy against neuroendocrine tumors. Other radiolabeled …

Aim: In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin
analogues, kidney uptake of radiolabelled compound is the major dose-limiting factor. We …

Megalin-mediated renal retention of radiolabeled somatostatin analogs may lead to
nephrotoxicity during peptide receptor radionuclide therapy (PRRT). The cytoprotective …

Background. Infusion of amino acids (AAs) can reduce renal uptake of radiolabelled
somatostatin analogues resulting in a lower kidney exposure during peptide radiotherapy of …

Purpose Renal irradiation is a dose-limiting factor in peptide receptor radionuclide therapy
using radiolabelled somatostatin analogues. This irradiation is mainly caused by …